UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000010858
Receipt number R000012710
Scientific Title The efficacy of remifentanil on the BIS values of patients who are treated with mECT:open-labeled single center non-randomized cross-over trial
Date of disclosure of the study information 2013/06/04
Last modified on 2021/12/09 17:23:10

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The efficacy of remifentanil on the BIS values of patients who are treated with mECT:open-labeled single center non-randomized cross-over trial

Acronym

The efficacy of remifentanil on the BIS values of patients who are treated with mECT

Scientific Title

The efficacy of remifentanil on the BIS values of patients who are treated with mECT:open-labeled single center non-randomized cross-over trial

Scientific Title:Acronym

The efficacy of remifentanil on the BIS values of patients who are treated with mECT

Region

Japan


Condition

Condition

Psychiatric disorders

Classification by specialty

Psychiatry Anesthesiology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

In the modified electroconvulsive therapy (mECT), shallow sedation leads to intraoperative memory, whereas deep sedation leads to insufficient convulsion. With remifentanil , of which anti-convulsive effect is small, we examine whether patients are sedated deeper than those treated with the conventional treatment, and sedated with no effect on the convulsion duration.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase



Assessment

Primary outcomes

the BIS value before the electrical stimulus,
the duration of the convulsion

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

In the interventional treatments, patients are sedated with remifentanil 1mcg/kg in addition to thiopental 3mg/kg.

Interventions/Control_2

In the control treatments, patients are sedated with thiopental 3mg/kg.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit

85 years-old >=

Gender

Male and Female

Key inclusion criteria

The study population consists of patients whose BIS values before the electrical stimuli are more than 60, when they are treated with Thymatron&#174; for the first time.

Key exclusion criteria

ASA PS 4 or 5
history of ischemic heart disease
history of heart disease as harmful as ischemic disease
allergies or contraindications to medications used in the trial

Target sample size

18


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Masahiko Shinozaki

Organization

Tokyo Metropolitan Health and Medical Treatment Corporation Toshima Hospital.

Division name

Department of Anesthesia

Zip code


Address

33-1 Sakaecho,Itabashi-Ku,Tokyo

TEL

03-5375-1234

Email



Public contact

Name of contact person

1st name
Middle name
Last name

Organization

Tokyo Metropolitan Health and Medical Treatment Corporation Toshima Hospital.

Division name

Department of Anesthesia

Zip code


Address

33-1 Sakaecho,Itabashi-Ku,Tokyo

TEL

03-5375-1234

Homepage URL


Email



Sponsor or person

Institute

Tokyo Metropolitan Health and Medical Treatment Corporation Toshima Hospital.
Department of Anesthesia.

Institute

Department

Personal name



Funding Source

Organization

Tokyo Metropolitan Health and Medical Treatment Corporation Toshima Hospital.

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2013 Year 06 Month 04 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2013 Year 05 Month 15 Day

Date of IRB

2016 Year 06 Month 07 Day

Anticipated trial start date

2013 Year 06 Month 07 Day

Last follow-up date

2016 Year 06 Month 07 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2013 Year 06 Month 03 Day

Last modified on

2021 Year 12 Month 09 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000012710


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name